An ongoing phase II study (NCT03257163) is evaluating pre-operative pembrolizumab followed by adjuvant immunotherapy and CRT in Mismatch-Repair Deficient (dMMR), Epstein–Barr virus-positive, and PD-L1-positive gastric cancers. This evidence concerns the gene CD274 and gastric cancer.